Long Noncoding RNA VPS9D1-AS1 Sequesters microRNA-525-5p to Promote the Oncogenicity of Colorectal Cancer Cells by Upregulating HMGA1
Authors Liu H, Zhang X, Jin X, Yang Y, Liang G, Ma Y, Wang B
Received 24 July 2020
Accepted for publication 3 September 2020
Published 9 October 2020 Volume 2020:12 Pages 9915—9928
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sanjeev Srivastava
Hairui Liu,1 Xueying Zhang,2 Xianmei Jin,3 Yubo Yang,1 Guodong Liang,1 Yuehan Ma,1 Bing Wang4
1Department of Abdominal Surgery, Jilin Cancer Hospital, Changchun, Jilin 130021, People’s Republic of China; 2Department of Oncology Medicine, Jilin Cancer Hospital, Changchun, Jilin 130021, People’s Republic of China; 3Department of Childhood Solid Tumor, First Hospital of Jilin University, Changchun, Jilin 130021, People’s Republic of China; 4Department of Radiotherapy, Jilin Cancer Hospital, Changchun, Jilin 130021, People’s Republic of China
Correspondence: Bing Wang
Department of Radiotherapy, Jilin Cancer Hospital, 1018, Huguang Road, Changchun, Jilin 130021, People’s Republic of China
Email [email protected]
Background: The long noncoding RNA VPS9D1 antisense RNA 1 (VPS9D1-AS1) has emerged as a critical regulator in non-small-cell lung, gastric, and prostate cancers. In this study, we measured the expression levels of VPS9D1-AS1 in colorectal cancer (CRC) and determined the role of VPS9D1-AS1 in regulating the biological activities of CRC cells. In addition, we thoroughly elucidated the molecular mechanism mediating the oncogenic activities of VPS9D1-AS1 in CRC.
Methods: The expression levels of VPS9D1-AS1 in CRC tissues and cell lines were detected via quantitative reverse transcription-polymerase chain reaction. Loss-of-function experiments were performed to detect the effects of VPS9D1-AS1 silencing on CRC cell proliferation, apoptosis, migration, and invasion as well as on tumor growth in vivo. Bioinformatics analysis predicted the potential microRNAs (miRNAs) interacting with VPS9D1-AS1, and this prediction was further confirmed via RNA immunoprecipitation and luciferase reporter assays.
Results: Our results demonstrated the upregulated expression of VPS9D1-AS1 in CRC tissues and cell lines. Functionally, VPS9D1-AS1 interference suppressed CRC cell proliferation, migration, and invasion and promoted cell apoptosis in vitro. In addition, the loss of VPS9D1-AS1 hindered tumor growth in vivo. Mechanistic studies identified VPS9D1-AS1 as a competing endogenous RNA in CRC cells, in which VPS9D1-AS1 acted as a molecular sponge of miR-525-5p and consequently increased the expression of high-mobility group AT-hook 1 (HMGA1). Moreover, rescue experiments revealed that the regulatory effects of VPS9D1-AS1 deficiency on CRC cells were abolished after miR-525-5p inhibition or HMGA1 restoration.
Conclusion: The newly identified competing endogenous RNA pathway involving VPS9D1-AS1, miR-525-5p, and HMGA1 is implicated in the control of CRC progression and may provide an effective target for CRC diagnosis and therapy.
Keywords: VPS9D1 antisense RNA 1, colorectal cancer, competing endogenous RNA model, therapeutic target
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]